Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: A cross-sectional study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Corporate Authors:
      KBASE Research Group
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science, [2004]-
    • Subject Terms:
      Alcohol Drinking/*metabolism ; Amyloid beta-Peptides/*metabolism ; Brain/*diagnostic imaging ; Cognitive Dysfunction/*diagnostic imaging; Aged ; Aged, 80 and over ; Alcohol Drinking/epidemiology ; Aniline Compounds ; Brain/metabolism ; Case-Control Studies ; Cognitive Dysfunction/epidemiology ; Cognitive Dysfunction/metabolism ; Cross-Sectional Studies ; Female ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Positron-Emission Tomography ; Protective Factors ; Republic of Korea/epidemiology ; Thiazoles
    • Abstract:
      Competing Interests: The authors have declared that no competing interests exist.
      Background: An emerging body of literature has indicated that moderate alcohol intake may be protective against Alzheimer disease (AD) dementia. However, little information is available regarding whether moderate alcohol intake is related to reductions in amyloid-beta (Aβ) deposition, or is protective via amyloid-independent mechanisms in the living human brain. Here we examined the associations of moderate alcohol intake with in vivo AD pathologies, including cerebral Aβ deposition, neurodegeneration of AD-signature regions, and cerebral white matter hyperintensities (WMHs) in the living human brain.
      Methods and Findings: The present study was part of the Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease (KBASE), an ongoing prospective cohort study that started in 2014. As of November 2016, 414 community-dwelling individuals with neither dementia nor alcohol-related disorders (280 cognitively normal [CN] individuals and 134 individuals with mild cognitive impairment [MCI]) between 56 and 90 years of age (mean age 70.9 years ± standard deviation 7.8; male, n [%] = 180 [43.5]) were recruited from 4 sites (i.e., 2 university hospitals and 2 public centers for dementia prevention and management) around Seoul, South Korea. All the participants underwent comprehensive clinical assessments comprising lifetime and current histories of alcohol intake and multimodal brain imaging, including [11C] Pittsburgh compound B positron emission tomography (PET), [18F] fluorodeoxyglucose (FDG) PET, and magnetic resonance imaging (MRI) scans. Lifetime and current alcohol intake were categorized as follows: no drinking, <1 standard drink (SD)/week, 1-13 SDs/week, and 14+ SDs/week. A moderate lifetime alcohol intake (1-13 SDs/week) was significantly associated with a lower Aβ positivity rate compared to the no drinking group, even after controlling for potential confounders (odds ratio 0.341, 95% confidence interval 0.163-0.714, p = 0.004). In contrast, current alcohol intake was not associated with amyloid deposition. Additionally, alcohol intake was not related to neurodegeneration of AD-signature regions or cerebral WMH volume. The present study had some limitations in that it had a cross-sectional design and depended on retrospective recall for alcohol drinking history.
      Conclusions: In this study, we observed in middle- and old-aged individuals with neither dementia nor alcohol-related disorders that moderate lifetime alcohol intake was associated with lower cerebral Aβ deposition compared to a lifetime history of not drinking. Moderate lifetime alcohol intake may have a beneficial influence on AD by reducing pathological amyloid deposition rather than amyloid-independent neurodegeneration or cerebrovascular injury.
    • References:
      JAMA. 2018 Aug 21;320(7):665-673. (PMID: 30140877)
      J Alzheimers Dis. 2009;17(1):7-31. (PMID: 19494429)
      Neuropsychologia. 2009 Oct;47(12):2464-9. (PMID: 19409401)
      JAMA. 2003 Mar 19;289(11):1405-13. (PMID: 12636463)
      J Int Neuropsychol Soc. 2004 Jan;10(1):72-81. (PMID: 14751009)
      Arch Neurol. 2008 Oct;65(10):1363-7. (PMID: 18852353)
      JAMA. 2015 May 19;313(19):1924-38. (PMID: 25988462)
      J Neurosci Res. 2009 Sep;87(12):2786-92. (PMID: 19382227)
      Am J Clin Nutr. 2004 Oct;80(4):992-7. (PMID: 15447910)
      Lancet. 2002 Jan 26;359(9303):281-6. (PMID: 11830193)
      Alzheimers Res Ther. 2013 Jan 25;5(1):3. (PMID: 23347747)
      Neurology. 1989 Sep;39(9):1159-65. (PMID: 2771064)
      Am J Geriatr Psychiatry. 2003 Jul-Aug;11(4):441-7. (PMID: 12837673)
      Free Radic Biol Med. 2007 Oct 1;43(7):1048-60. (PMID: 17761301)
      Brain. 2015 Jul;138(Pt 7):2020-33. (PMID: 25953778)
      N Engl J Med. 2005 Jan 20;352(3):245-53. (PMID: 15659724)
      FASEB J. 2006 Nov;20(13):2313-20. (PMID: 17077308)
      J Clin Epidemiol. 2002 Oct;55(10):959-64. (PMID: 12464371)
      Neurobiol Aging. 2015 Feb;36(2):845-56. (PMID: 25433458)
      Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820-5. (PMID: 19346482)
      Alcohol Clin Exp Res. 2006 Jun;30(6):1045-50. (PMID: 16737464)
      Alcohol Alcohol. 2001 Sep-Oct;36(5):357-68. (PMID: 11524299)
      Am J Epidemiol. 2004 Aug 1;160(3):240-7. (PMID: 15257997)
      Ann Epidemiol. 2007 Feb;17(2):93-9. (PMID: 17027288)
      Age Ageing. 2007 May;36(3):256-61. (PMID: 17353234)
      Age Ageing. 2008 Sep;37(5):505-12. (PMID: 18487267)
      Free Radic Biol Med. 1999 Jul;27(1-2):160-9. (PMID: 10443932)
      Neuropharmacology. 2011 Dec;61(8):1406-12. (PMID: 21903110)
      Psychiatry Investig. 2008 Dec;5(4):232-8. (PMID: 20046343)
      Stroke. 2001 Sep;32(9):1939-46. (PMID: 11546878)
      Neurobiol Aging. 2014 Jul;35(7):1519-25. (PMID: 24524964)
      Lancet Psychiatry. 2015 Aug;2(8):674-675. (PMID: 26249282)
      Neurology. 2004 Jul 27;63(2):220-7. (PMID: 15277612)
      Lancet. 1991 May 11;337(8750):1158-9. (PMID: 1674030)
      Lancet Neurol. 2014 Oct;13(10):997-1005. (PMID: 25201514)
      Arch Med Res. 2013 Jan;44(1):1-7. (PMID: 23291379)
      Free Radic Biol Med. 2003 Apr 1;34(7):810-7. (PMID: 12654468)
      BMJ. 2017 Jun 6;357:j2353. (PMID: 28588063)
      J Gerontol A Biol Sci Med Sci. 2009 Apr;64(4):481-6. (PMID: 19213852)
      Age Ageing. 2011 Jul;40(4):456-63. (PMID: 21367764)
      Eur J Epidemiol. 2017 Jan;32(1):31-42. (PMID: 28097521)
      Dement Geriatr Cogn Disord. 2007;23(3):140-9. (PMID: 17170526)
      BMJ. 2010 Jul 26;341:c3666. (PMID: 20660506)
      Psychosom Med. 2006 Sep-Oct;68(5):778-85. (PMID: 17012533)
      Brain Res. 2002 Dec 27;958(2):439-47. (PMID: 12470882)
      Alcohol Alcohol. 2009 Mar-Apr;44(2):136-40. (PMID: 19147798)
      J Mol Cell Cardiol. 2004 Apr;36(4):561-6. (PMID: 15081315)
      Psychiatry Investig. 2012 Mar;9(1):8-16. (PMID: 22396679)
      J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P47-53. (PMID: 11773223)
      Hum Psychopharmacol. 2009 Apr;24(3):199-205. (PMID: 19330800)
      Psychiatry Investig. 2017 Nov;14(6):851-863. (PMID: 29209391)
      Neurology. 1993 Nov;43(11):2412-4. (PMID: 8232972)
      J Alzheimers Dis. 2016 Jun 18;53(3):1097-105. (PMID: 27340843)
    • Accession Number:
      0 (2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole)
      0 (Amyloid beta-Peptides)
      0 (Aniline Compounds)
      0 (Thiazoles)
    • Publication Date:
      Date Created: 20200226 Date Completed: 20200518 Latest Revision: 20200518
    • Publication Date:
      20250114
    • Accession Number:
      PMC7041799
    • Accession Number:
      10.1371/journal.pmed.1003022
    • Accession Number:
      32097439